207 related articles for article (PubMed ID: 20511188)
1. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
2. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
3. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
4. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
6. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
[TBL] [Abstract][Full Text] [Related]
8. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
9. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
Dubuisson A; Favreau C; Fourmaux E; Lareure S; Rodrigues-Saraiva R; Pellat-Deceunynck C; El Alaoui S; Micheau O
Cell Death Dis; 2019 Feb; 10(2):101. PubMed ID: 30718507
[TBL] [Abstract][Full Text] [Related]
11. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand.
Nagane M; Cavenee WK; Shiokawa Y
J Neurosurg; 2007 Mar; 106(3):407-16. PubMed ID: 17367063
[TBL] [Abstract][Full Text] [Related]
13. Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.
Xu ZF; Sun XK; Lan Y; Han C; Zhang YD; Chen G
Biomed Pharmacother; 2017 Nov; 95():1607-1618. PubMed ID: 28950661
[TBL] [Abstract][Full Text] [Related]
14. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
[TBL] [Abstract][Full Text] [Related]
15. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
Zhang L; Zhang X; Barrisford GW; Olumi AF
Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
[TBL] [Abstract][Full Text] [Related]
16. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells.
Zou W; Liu X; Yue P; Khuri FR; Sun SY
Cancer Biol Ther; 2007 Jan; 6(1):99-106. PubMed ID: 17172826
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
19. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
20. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
